drug_type
RELEVANT_DRUG
intervention_type
Biological (cellular therapy)
drug_description
Autologous TCR-engineered T cell therapy targeting an HPV18-derived peptide presented by HLA-DRB1*0901; infused T cells recognize HPV18+ tumor cells and mediate cytotoxicity via TCR signaling, cytokine release, and perforin/granzyme pathways.
nci_thesaurus_concept_id
C200468
nci_thesaurus_definition
A preparation of genetically engineered T-lymphocytes expressing a T-cell receptor (TCR) targeting a specific tumor-associated antigen (TAA) of the human papillomavirus (HPV) type 18 (HPV-18), with potential antineoplastic activity. Upon administration, HPV-18 expressing TCR T-cells target and bind to tumor cells expressing the HPV-18 TAA leading to selective cytotoxicity in HPV-18 TAA-expressing tumor cells. HPV18 TAAs are overexpressed in a variety of tumor cell types.
drug_mesh_term
T-Lymphocytes, Genetically Modified
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are engineered to express a T-cell receptor that recognizes an HPV18-derived peptide presented by HLA-DRB1*0901 on tumor cells. Antigen recognition activates TCR signaling, leading to cytokine release and cytotoxic killing via perforin/granzyme pathways, selectively eliminating HPV18-positive tumor cells.
drug_name
HRYZ-T101
nct_id_drug_ref
NCT05952947